# Amplitude, Inc.: financial statements, quarterly

AMPL · Nasdaq · CIK 1866692 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ampl.md) · [Financials](/companies/ampl/financials.md) · [Filings](/companies/ampl/filings.md) · [Insiders](/companies/ampl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ampl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [70.6](/filings/0000950170-24-123339.md) | [71.4 d](/filings/0001193125-26-057847.md) | [72.6](/filings/0000950170-25-065639.md) | [73.3](/filings/0000950170-25-104357.md) | [75.2](/filings/0001193125-25-267492.md) | [78.1 d](/filings/0001193125-26-057847.md) | [80.0](/filings/0001193125-26-209631.md) | [83.3](/filings/0001193125-26-335706.md) | [88.6](/filings/0001193125-25-267492.md) | [91.4 d](/filings/0001193125-26-057847.md) | [93.5](/filings/0001193125-26-209631.md) | [101](/filings/0001193125-26-335706.md) |
| Cost of revenue | $m | [17.3](/filings/0000950170-24-123339.md) | [18.3 d](/filings/0001193125-26-057847.md) | [18.9](/filings/0000950170-25-065639.md) | [19.5](/filings/0000950170-25-104357.md) | [18.7](/filings/0001193125-25-267492.md) | [19.8 d](/filings/0001193125-26-057847.md) | [20.2](/filings/0001193125-26-209631.md) | [22.8](/filings/0001193125-26-335706.md) | [23.1](/filings/0001193125-25-267492.md) | [23.2 d](/filings/0001193125-26-057847.md) | [25.2](/filings/0001193125-26-209631.md) | [31.8](/filings/0001193125-26-335706.md) |
| Gross profit | $m | [53.3](/filings/0000950170-24-123339.md) | [53.1 d](/filings/0001193125-26-057847.md) | [53.7](/filings/0000950170-25-065639.md) | [53.8](/filings/0000950170-25-104357.md) | [56.5](/filings/0001193125-25-267492.md) | [58.3 d](/filings/0001193125-26-057847.md) | [59.7](/filings/0001193125-26-209631.md) | [60.5](/filings/0001193125-26-335706.md) | [65.5](/filings/0001193125-25-267492.md) | [68.2 d](/filings/0001193125-26-057847.md) | [68.3](/filings/0001193125-26-209631.md) | [69.1](/filings/0001193125-26-335706.md) |
| Research and development | $m | [21.8](/filings/0000950170-24-123339.md) | [22.2 d](/filings/0001193125-26-057847.md) | [23.0](/filings/0000950170-25-065639.md) | [21.1](/filings/0000950170-25-104357.md) | [19.0](/filings/0001193125-25-267492.md) | [34.4 d](/filings/0001193125-26-057847.md) | [23.5](/filings/0001193125-26-209631.md) | [24.1](/filings/0001193125-26-335706.md) | [26.6](/filings/0001193125-25-267492.md) | [23.3 d](/filings/0001193125-26-057847.md) | [25.3](/filings/0001193125-26-209631.md) | [33.7](/filings/0001193125-26-335706.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(27.1)](/filings/0001193125-26-335706.md) | not reported | not reported | not reported | [(35.2)](/filings/0001193125-26-335706.md) |
| Income tax | $m | [0.3](/filings/0000950170-24-123339.md) | [0.5 d](/filings/0001193125-26-057847.md) | [0.4](/filings/0000950170-25-065639.md) | [0.2](/filings/0000950170-25-104357.md) | [0.7](/filings/0001193125-25-267492.md) | [0.4 d](/filings/0001193125-26-057847.md) | [0.8](/filings/0001193125-26-209631.md) | [0.6](/filings/0001193125-26-335706.md) | [0.9](/filings/0001193125-25-267492.md) | [0.9 d](/filings/0001193125-26-057847.md) | [1.1](/filings/0001193125-26-209631.md) | [1.2](/filings/0001193125-26-335706.md) |
| Net income | $m | [(17.7)](/filings/0000950170-24-123339.md) | [(18.5) d](/filings/0001193125-26-057847.md) | [(21.5)](/filings/0001193125-25-267492.md) | [(23.4)](/filings/0001193125-25-267492.md) | [(16.9)](/filings/0001193125-25-267492.md) | [(32.6) d](/filings/0001193125-26-057847.md) | [(22.2)](/filings/0001193125-26-335706.md) | [(24.7)](/filings/0001193125-26-335706.md) | [(24.0)](/filings/0001193125-25-267492.md) | [(17.7) d](/filings/0001193125-26-057847.md) | [(23.3)](/filings/0001193125-26-335706.md) | [(34.6)](/filings/0001193125-26-335706.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0000950170-24-123339.md) | not reported | [(0.18)](/filings/0000950170-25-065639.md) | [(0.19)](/filings/0000950170-25-104357.md) | [(0.14)](/filings/0001193125-25-267492.md) | not reported | [(0.17)](/filings/0001193125-26-209631.md) | [(0.19)](/filings/0001193125-26-335706.md) | [(0.18)](/filings/0001193125-25-267492.md) | not reported | [(0.17)](/filings/0001193125-26-209631.md) | [(0.27)](/filings/0001193125-26-335706.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0000950170-24-123339.md) | not reported | [(0.18)](/filings/0000950170-25-065639.md) | [(0.19)](/filings/0000950170-25-104357.md) | [(0.14)](/filings/0001193125-25-267492.md) | not reported | [(0.17)](/filings/0001193125-26-209631.md) | [(0.19)](/filings/0001193125-26-335706.md) | [(0.18)](/filings/0001193125-25-267492.md) | not reported | [(0.17)](/filings/0001193125-26-209631.md) | [(0.27)](/filings/0001193125-26-335706.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [239](/filings/0000950170-24-123339.md) | [248](/filings/0000950170-25-065639.md) | [266](/filings/0000950170-25-065639.md) | [282](/filings/0000950170-24-093925.md) | [317](/filings/0000950170-24-123339.md) | [172](/filings/0001193125-26-057847.md) | [131](/filings/0000950170-25-065639.md) | [120](/filings/0000950170-25-104357.md) | [82.2](/filings/0001193125-25-267492.md) | [81.1](/filings/0001193125-26-335706.md) | [86.6](/filings/0001193125-26-209631.md) | [73.8](/filings/0001193125-26-335706.md) |
| Current assets | $m | [386](/filings/0000950170-23-060240.md) | [380](/filings/0000950170-25-024135.md) | [384](/filings/0000950170-24-056922.md) | [388](/filings/0000950170-24-093925.md) | [388](/filings/0000950170-24-123339.md) | [304](/filings/0001193125-26-057847.md) | [286](/filings/0000950170-25-065639.md) | [287](/filings/0000950170-25-104357.md) | [266](/filings/0001193125-25-267492.md) | [257](/filings/0001193125-26-335706.md) | [263](/filings/0001193125-26-209631.md) | [220](/filings/0001193125-26-335706.md) |
| Total assets | $m | [441](/filings/0000950170-23-060240.md) | [434](/filings/0000950170-25-024135.md) | [438](/filings/0000950170-24-056922.md) | [445](/filings/0000950170-24-093925.md) | [446](/filings/0000950170-24-123339.md) | [446](/filings/0001193125-26-057847.md) | [446](/filings/0000950170-25-065639.md) | [457](/filings/0000950170-25-104357.md) | [438](/filings/0001193125-25-267492.md) | [421](/filings/0001193125-26-335706.md) | [402](/filings/0001193125-26-209631.md) | [357](/filings/0001193125-26-335706.md) |
| Current liabilities | $m | [142](/filings/0000950170-23-060240.md) | [132](/filings/0000950170-25-024135.md) | [144](/filings/0000950170-24-056922.md) | [154](/filings/0000950170-24-093925.md) | [152](/filings/0000950170-24-123339.md) | [145](/filings/0001193125-26-057847.md) | [151](/filings/0000950170-25-065639.md) | [171](/filings/0000950170-25-104357.md) | [171](/filings/0001193125-25-267492.md) | [165](/filings/0001193125-26-335706.md) | [174](/filings/0001193125-26-209631.md) | [210](/filings/0001193125-26-335706.md) |
| Total liabilities | $m | [150](/filings/0000950170-23-060240.md) | [139](/filings/0000950170-25-024135.md) | [149](/filings/0000950170-24-056922.md) | [158](/filings/0000950170-24-093925.md) | [156](/filings/0000950170-24-123339.md) | [149](/filings/0001193125-26-057847.md) | [156](/filings/0000950170-25-065639.md) | [177](/filings/0000950170-25-104357.md) | [176](/filings/0001193125-25-267492.md) | [175](/filings/0001193125-26-335706.md) | [184](/filings/0001193125-26-209631.md) | [220](/filings/0001193125-26-335706.md) |
| Shareholders' equity | $m | [292](/filings/0000950170-24-123339.md) | [295](/filings/0001193125-26-057847.md) | [289](/filings/0001193125-25-267492.md) | [287](/filings/0001193125-25-267492.md) | [290](/filings/0001193125-25-267492.md) | [297](/filings/0001193125-26-335706.md) | [289](/filings/0001193125-26-335706.md) | [280](/filings/0001193125-26-335706.md) | [262](/filings/0001193125-25-267492.md) | [245](/filings/0001193125-26-335706.md) | [217](/filings/0001193125-26-335706.md) | [136](/filings/0001193125-26-335706.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [8.0 d](/filings/0000950170-24-123339.md) | [2.3 d](/filings/0001193125-26-057847.md) | [(0.0)](/filings/0000950170-25-065639.md) | [9.2 d](/filings/0000950170-25-104357.md) | [6.2 d](/filings/0001193125-25-267492.md) | [3.2 d](/filings/0001193125-26-057847.md) | [(8.0)](/filings/0001193125-26-209631.md) | [20.1 d](/filings/0001193125-26-335706.md) | [5.0 d](/filings/0001193125-25-267492.md) | [12.8 d](/filings/0001193125-26-057847.md) | [(11.6)](/filings/0001193125-26-209631.md) | [25.6 d](/filings/0001193125-26-335706.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123339.md) | [0.3 d](/filings/0001193125-26-057847.md) | [0.4](/filings/0000950170-25-065639.md) | [0.6 d](/filings/0000950170-25-104357.md) | [0.0 d](/filings/0001193125-25-267492.md) | [0.7 d](/filings/0001193125-26-057847.md) | [0.4](/filings/0001193125-26-209631.md) | [0.5 d](/filings/0001193125-26-335706.md) | [0.5 d](/filings/0001193125-25-267492.md) | [0.2 d](/filings/0001193125-26-057847.md) | [0.4](/filings/0001193125-26-209631.md) | [1.2 d](/filings/0001193125-26-335706.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-267492.md) | [0.0 d](/filings/0001193125-26-057847.md) | [0.0](/filings/0001193125-26-209631.md) | [2.5](/filings/0001193125-26-335706.md) | [11.7](/filings/0001193125-25-267492.md) | [16.5 d](/filings/0001193125-26-057847.md) | [20.7](/filings/0001193125-26-335706.md) | [68.7](/filings/0001193125-26-335706.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [112](/filings/0000950170-23-060240.md) | [114](/filings/0000950170-24-056922.md) | [116](/filings/0000950170-24-093925.md) | [118](/filings/0000950170-24-123339.md) | [121](/filings/0000950170-25-065639.md) | [123](/filings/0000950170-25-104357.md) | [124](/filings/0001193125-25-267492.md) | [130](/filings/0001193125-26-209631.md) | [131](/filings/0001193125-26-335706.md) | [133](/filings/0001193125-25-267492.md) | [133](/filings/0001193125-26-209631.md) | [129](/filings/0001193125-26-335706.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.